CN106581236A - Medicinal composition for promoting gastric motility, and preparation method and application thereof - Google Patents
Medicinal composition for promoting gastric motility, and preparation method and application thereof Download PDFInfo
- Publication number
- CN106581236A CN106581236A CN201611192811.1A CN201611192811A CN106581236A CN 106581236 A CN106581236 A CN 106581236A CN 201611192811 A CN201611192811 A CN 201611192811A CN 106581236 A CN106581236 A CN 106581236A
- Authority
- CN
- China
- Prior art keywords
- extract
- pharmaceutical composition
- gastric motility
- fructus aurantii
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000030135 gastric motility Effects 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 230000001737 promoting effect Effects 0.000 title claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 129
- 239000003814 drug Substances 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 48
- 239000008194 pharmaceutical composition Substances 0.000 claims description 38
- 241000208340 Araliaceae Species 0.000 claims description 37
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 37
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 37
- 235000008434 ginseng Nutrition 0.000 claims description 37
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 238000010992 reflux Methods 0.000 claims description 17
- 229950005162 benexate Drugs 0.000 claims description 16
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 claims description 16
- 239000000341 volatile oil Substances 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 229920000858 Cyclodextrin Polymers 0.000 claims description 8
- 239000001116 FEMA 4028 Substances 0.000 claims description 8
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 8
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 8
- 229960004853 betadex Drugs 0.000 claims description 8
- 238000002137 ultrasound extraction Methods 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 238000002390 rotary evaporation Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims 1
- 239000003610 charcoal Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 241000554432 Isodon amethystoides Species 0.000 abstract description 4
- 235000002789 Panax ginseng Nutrition 0.000 abstract 3
- 238000009776 industrial production Methods 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 description 26
- 229930003944 flavone Natural products 0.000 description 15
- 150000002213 flavones Chemical class 0.000 description 15
- 235000011949 flavones Nutrition 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000012467 final product Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 229930003347 Atropine Natural products 0.000 description 5
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 5
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 5
- 229960000396 atropine Drugs 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical group C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- -1 3 times Substances 0.000 description 2
- 244000183685 Citrus aurantium Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960001253 domperidone Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a medicinal composition for promoting gastric motility. The medicinal composition comprises Rabdosia amethystoides extract, Fructus Aurantii extract and red ginseng extract, wherein a mass ratio of the Rabdosia amethystoides extract to the Fructus Aurantii extract to the red ginseng extract is (1-2):(5-10):(10-60). A preparation method of the medicinal composition is characterized in that the Rabdosia amethystoides extract, the Fructus Aurantii extract and the red ginseng extract are uniformly mixed according to the mass ratio of (1-2):(5-10):(10-60) to obtain the medicinal composition. The preparation method is simple, and is suitable for industrial production. The invention also provides an application of the medicinal composition in the preparation of medicines for promoting gastric motility. The medicinal composition can effectively promote the gastric motility, and has small side effects.
Description
Technical field
The present invention relates to pharmaceutical technology field, and in particular to a kind of pharmaceutical composition of promotion gastric motility and preparation method thereof
And application.
Background technology
Gastric motility refers to the contraction peristaltic forces of stomach muscle, including the strength and frequency of stomach muscle contraction.Gastric motility
Deficiency, is also " dyspepsia ".Gastric motility disorder is the main cause for causing non-ucler dyspepsia.When the gastric motility of people goes out
During existing obstacle, it may occur that upper abdomen distension, the easily full, indigestion symptom such as abdominal distention, Nausea and vomiting after meal.
Doctor trained in Western medicine thinks digestive tract mechanical movement obstacle and disorder caused by the pathogeny of gastric motility disorder and a variety of causes, stomach
It is relevant that emptying delay causes gastric motility to decline.Existing gastric motility medicine is a lot, and major part is Western medicine, there is different degrees of secondary work
With being not suitable for long-term taking.At present to the use of Chinese medicine prescription mainly based on decoction, but these Chinese medicine decoction have
Pharmacotoxicological effect is indefinite, dosage is inaccurate, quality control is poor and in-convenience in use waits weak point.Therefore, Ren Menxi
While prestige can over the course for the treatment of avoid Western medicine toxic and side effects, can develop in Chinese medicine prescription with promotion gastric motility
Effect, improve gastrointestinal dysfunction and the less Chinese patent medicine of toxic and side effects come reach treatment disease purpose.
Herba Rabdosiae glaucocalycis are the aerial partss of labiate Herba Rabdosiae glaucocalycis Rabdosia amethystoides (Benth.) Hara.
It is distributed in the ground such as Jiangsu, Anhui, Zhejiang, Jiangxi, Fujian, Taiwan, Hubei, Guangdong, Guangxi, Guizhou.With clearing away heat-damp and promoting diuresis, promoting blood circulation
The effect of dissipating blood stasis, removing toxic substances and promoting subsidence of swelling.For jaundice due to damp-heat, stranguria, edema, laryngopharynx swelling and pain, arthralgia, amenorrhea, acute mastitis, hemorrhoid,
Carbuncle on the back, traumatic injury, venom.
Fructus Aurantii is《Chinese Pharmacopoeia》The medical herbs included, medicinal source is rutaceae Citrus aurantium Linn. Citrus aurantium
And its variety is dried immature fruit L..Harvest when July peel is still green, it is crosscutting for two halves from middle part, dry or low temperature
It is dried.Fructus Aurantii property is bitter, pungent, sour, temperature, has functions that regulating the flow of QI to ease the stomach, the stagnant relieving distension of row, cures mainly the chest side of body stagnation of QI, distension pain, food stagnation
Do not change, stop in phlegm retention；The diseases such as gastroptosis, proctoptosis, sub-official prolapses.
The content of the invention
It is an object of the invention to provide a kind of reasonable recipe, the eutherapeutic pharmaceutical composition of promotion gastric motility and its preparation side
Method and application.
A kind of pharmaceutical composition of promotion gastric motility, is made up of Herba Rabdosiae glaucocalycis extract, Fructus Aurantii extract and Radix Ginseng Rubra extract,
Wherein, the mass ratio of Herba Rabdosiae glaucocalycis extract, Fructus Aurantii extract and Radix Ginseng Rubra extract is 1～2：5～10：10～60.
The present invention uses rational extracting method, with reference to the synergistic function of Herba Rabdosiae glaucocalycis, Fructus Aurantii and Radix Ginseng Rubra, can be effectively
Promote gastric motility, Small side effects.
Preferably, in described pharmaceutical composition, the mass ratio of Herba Rabdosiae glaucocalycis extract, Fructus Aurantii extract and Radix Ginseng Rubra extract
For 1：6：20～40.
Preferably, in aforementioned pharmaceutical compositions, edible or pharmaceutic adjuvant can be added, including：Excipient, flavoring agent,
Diluent, suspending agent, antioxidant, emulsifying agent, thickening agent, solubilizing agent, filler, lubricant, wetting agent, disintegrating agent, bonding
Agent and at least one of the preservatives.
Present invention also offers a kind of preparation method of the pharmaceutical composition of promotion gastric motility, specially：Herba Rabdosiae glaucocalycis are carried
Thing, Fructus Aurantii extract and Radix Ginseng Rubra extract are taken with mass ratio as 1～2：5～10：10～60 mix homogeneously, obtain the drug regimen
Thing.
The preparation method of the Herba Rabdosiae glaucocalycis extract includes：Addition ethanol ultrasonic extraction 2～3 times in Herba Rabdosiae glaucocalycis, every time
20～40min, the alcohol extract for obtaining plus activated carbon reflux decolour are extracted, is centrifuged, filtrate is concentrated into extractum, molten with ethyl acetate
Solution, plus saturated sodium carbonate solution shaking extraction, ethyl acetate layer is concentrated to dryness, finely ground.The scented tea that this extracting method is extracted
Dish extract improves the effective content of liposoluble constituent, can be with effectively treatment gastric motility.
Preferably, the mass fraction of the ethanol is 40～80%, dosage is 3～10 times of Herba Rabdosiae glaucocalycis quality.
Preferably, the dosage of the activated carbon is the 3～8% of Herba Rabdosiae glaucocalycis crude drug quality.
Preferably, the dosage of the saturated sodium carbonate solution is the 3～8% of ethyl acetate quality.
The preparation method of the Fructus Aurantii extract includes：Take Fructus Aurantii to pulverize and sieve, add water backflow 4～6 hours, connection volatilization
Oil extractor and reflux condensing tube, gained volatile oil beta-cyclodextrin inclusion compound makes Benexate Hydrochloride, and remaining medicinal residues add water
Decoct, filter, decocting liquid crosses AB-8 type macroporous resins, and with 3～6 times of ethanol elutions of column volume 50%, eluent rotary evaporation is dense
After contracting is dried, gained total flavones mix with Benexate Hydrochloride, obtain the Fructus Aurantii extract.What this extracting method was extracted
Fructus Aurantii extract had both reduced the loss of volatile oil, and the content of total flavones is improve again.
In the preparation of the Fructus Aurantii extract, before the backflow that adds water, Fructus Aurantii is crushed, make the larger medical material of volume become adult
The little medical material of little, the easy infiltration of product, increases medical material and water vapour contact area, accelerates water vapour immersion medical material tissue, cell, increases
Volatile ingredient is effectively extracted cleaner, thoroughly to external diffusion by fast volatile ingredient, improves extract yield and effectively
Component content, is conducive to formulation products steady quality and medicament curative effect enhancement.Preferably, before the backflow that adds water, by Fructus Aurantii powder
The mesh sieve of broken mistake 10.
Preferably, amount of water is 3～8 times of Fructus Aurantii crude drug quality.
The weight/mass percentage composition of total flavones is 25%～40% in the Fructus Aurantii extract.
Described Radix Ginseng Rubra extract can adopt commercially available prod, also can voluntarily prepare, and its preparation method can refer to《Chinese herbal medicine into
Differentiation is learned》Described in method carry out, specifically include step：By Radix Ginseng Rubra crushing, ethanol or water reflux, extract, cold preservation, filtration, filter
Liquid concentration, vacuum drying, obtain final product Radix Ginseng Rubra extract.
The preparation method of the pharmaceutical composition of above-mentioned promotion gastric motility, also includes：By obtained pharmaceutical composition, directly or
Person adds edible or pharmaceutic adjuvant, further makes capsule, tablet, granule, oral liquid by conventional pharmacy means
Or powder.
It is a further object of the present invention to provide a kind of promote the pharmaceutical composition of gastric motility preparing promotion gastric motility medicine
In application.
Compared with the existing technology, the invention has the advantages that：The present invention uses rational extracting method, improves
The content of effective ingredient, with reference to the synergistic function of Herba Rabdosiae glaucocalycis, Fructus Aurantii and Radix Ginseng Rubra, can be effectively promoted gastric motility, side effect
It is little.
Specific embodiment
Embodiment 1
(1) preparation of Herba Rabdosiae glaucocalycis extract：6 times of addition, 80% ethanol ultrasonic extraction of amount 2 times, extracts every time in Herba Rabdosiae glaucocalycis
40min, the alcohol extract for obtaining adds activated carbon reflux decolour, and the dosage of activated carbon is the 3% of Herba Rabdosiae glaucocalycis crude drug quality, from
The heart, filtrate is concentrated into extractum, is dissolved with ethyl acetate, plus saturated sodium carbonate solution shaking is extracted, and ethyl acetate layer is concentrated to dryness,
It is finely ground.
(2) preparation of Fructus Aurantii extract：Take Fructus Aurantii and crushed 10 mesh sieves, add water backflow 4 hours, connects volatile oil extractor
With reflux condensing tube, gained volatile oil beta-cyclodextrin inclusion compound makes Benexate Hydrochloride, and remaining medicinal residues add 3 times of amount decoctings
Boil, filter, decocting liquid crosses AB-8 type macroporous resins, with 4 times of ethanol elutions of column volume 50%, eluent rotary evaporation concentrate drying
Afterwards, gained total flavones mix with Benexate Hydrochloride, obtain final product Fructus Aurantii extract, the quality of total flavones in gained Fructus Aurantii extract
Percentage composition is 38%.
(3) preparation of Radix Ginseng Rubra extract：Add 5 times of 80% ethanol of amount to extract in Radix Ginseng Rubra 3 times, extract 1.5 hours every time,
The alcohol extract for obtaining is filtered, filtrate concentrates, is vacuum dried to obtain Radix Ginseng Rubra extract.
(4) by Herba Rabdosiae glaucocalycis extract, Fructus Aurantii extract and Radix Ginseng Rubra extract with mass ratio as 1：6：40 mix homogeneously, 80 mesh
Sieve, obtain pharmaceutical composition powder of the particle diameter less than 80 mesh, fill capsule.Promotion gastric motility is made in the irradiated sterilizing of capsule
Medicament composition capsule.
Embodiment 2
(1) preparation of Herba Rabdosiae glaucocalycis extract：5 times of addition, 60% ethanol ultrasonic extraction of amount 3 times, extracts every time in Herba Rabdosiae glaucocalycis
30min, the alcohol extract for obtaining adds activated carbon reflux decolour, and the dosage of activated carbon is the 5% of Herba Rabdosiae glaucocalycis crude drug quality, from
The heart, filtrate is concentrated into extractum, is dissolved with ethyl acetate, plus saturated sodium carbonate solution shaking is extracted, and ethyl acetate layer is concentrated to dryness,
It is finely ground.
(2) preparation of Fructus Aurantii extract：Take Fructus Aurantii and crushed 9 mesh sieves, add water backflow 5 hours, connects volatile oil extractor
With reflux condensing tube, gained volatile oil beta-cyclodextrin inclusion compound makes Benexate Hydrochloride, and remaining medicinal residues add 4 times of amount decoctings
Boil, filter, decocting liquid crosses AB-8 type macroporous resins, with 5 times of ethanol elutions of column volume 50%, eluent rotary evaporation concentrate drying
Afterwards, gained total flavones mix with Benexate Hydrochloride, obtain final product Fructus Aurantii extract, the quality of total flavones in gained Fructus Aurantii extract
Percentage composition is 27%.
(3) preparation of Radix Ginseng Rubra extract：Add 5 times of 60% ethanol of amount to extract in Radix Ginseng Rubra 3 times, extract 2 hours every time, obtain
To alcohol extract filter, filtrate concentration, be vacuum dried to obtain Radix Ginseng Rubra extract.
(4) by Herba Rabdosiae glaucocalycis extract, Fructus Aurantii extract and Radix Ginseng Rubra extract with mass ratio as 2：6：45 mix homogeneously, obtain
Particle diameter is less than the pharmaceutical composition powder of 90 mesh, fill capsule.The medicine group for promoting gastric motility is made in the irradiated sterilizing of capsule
Compound capsule.
Embodiment 3
(1) preparation of Herba Rabdosiae glaucocalycis extract：8 times of addition, 40% ethanol ultrasonic extraction of amount 3 times, extracts every time in Herba Rabdosiae glaucocalycis
20min, the alcohol extract for obtaining adds activated carbon reflux decolour, and the dosage of activated carbon is the 8% of Herba Rabdosiae glaucocalycis crude drug quality, from
The heart, filtrate is concentrated into extractum, is dissolved with ethyl acetate, plus saturated sodium carbonate solution shaking is extracted, and ethyl acetate layer is concentrated to dryness,
It is finely ground.
(2) preparation of Fructus Aurantii extract：Take Fructus Aurantii and crushed 12 mesh sieves, add water backflow 6 hours, connects volatile oil extractor
With reflux condensing tube, gained volatile oil beta-cyclodextrin inclusion compound makes Benexate Hydrochloride, and remaining medicinal residues add 3 times of amount decoctings
Boil, filter, decocting liquid crosses AB-8 type macroporous resins, with 3 times of ethanol elutions of column volume 50%, eluent rotary evaporation concentrate drying
Afterwards, gained total flavones mix with Benexate Hydrochloride, obtain final product Fructus Aurantii extract, the quality of total flavones in gained Fructus Aurantii extract
Percentage composition is 30%.
(3) preparation of Radix Ginseng Rubra extract：8 times of addition amount water reflux, extract, 3 times, extracts 1.5 hours every time in Radix Ginseng Rubra, obtains
To extracting solution filter, filtrate concentration, be vacuum dried to obtain Radix Ginseng Rubra extract.
(4) by Herba Rabdosiae glaucocalycis extract, Fructus Aurantii extract and Radix Ginseng Rubra extract with mass ratio as 1：6：20 mix homogeneously, 100
Mesh sieves, and obtains pharmaceutical composition powder of the particle diameter less than 100 mesh, then by the pharmaceutical composition powder and cellulose with mass ratio
For 1：1 mixing is abundant, tabletting, coating, makes tablet, and the pharmaceutical composition for promoting gastric motility is made in the irradiated sterilizing of tablet
Piece.
Embodiment 4
(1) preparation of Herba Rabdosiae glaucocalycis extract：4 times of addition, 70% ethanol ultrasonic extraction of amount 3 times, extracts every time in Herba Rabdosiae glaucocalycis
30min, the alcohol extract for obtaining adds activated carbon reflux decolour, and the dosage of activated carbon is the 6% of Herba Rabdosiae glaucocalycis crude drug quality, from
The heart, filtrate is concentrated into extractum, is dissolved with ethyl acetate, plus saturated sodium carbonate solution shaking is extracted ethyl acetate layer and is concentrated to dryness,
It is finely ground.
(2) preparation of Fructus Aurantii extract：Take Fructus Aurantii and crushed 10 mesh sieves, add water backflow 5 hours, connects volatile oil extractor
With reflux condensing tube, gained volatile oil beta-cyclodextrin inclusion compound makes Benexate Hydrochloride, and remaining medicinal residues add 4 times of amount decoctings
Boil, filter, decocting liquid crosses AB-8 type macroporous resins, with 4 times of ethanol elutions of column volume 50%, eluent rotary evaporation concentrate drying
Afterwards, gained total flavones mix with Benexate Hydrochloride, obtain final product Fructus Aurantii extract, the quality of total flavones in gained Fructus Aurantii extract
Percentage composition is 40%.
(3) preparation of Radix Ginseng Rubra extract：9 times of addition amount water reflux, extract, 2 times, extracts 1 hour every time in Radix Ginseng Rubra, obtains
Extracting solution filter, filtrate concentration, be vacuum dried to obtain Radix Ginseng Rubra extract.
(4) by Herba Rabdosiae glaucocalycis extract, Fructus Aurantii extract and Radix Ginseng Rubra extract with mass ratio as 2：9：25 mix homogeneously, 80 mesh
Sieve, obtain pharmaceutical composition powder of the particle diameter less than 80 mesh, then be with mass ratio by the pharmaceutical composition powder and cellulose
1：1 mixing is abundant, tabletting, coating, makes tablet, and the pharmaceutical composition piece for promoting gastric motility is made in the irradiated sterilizing of tablet.
Comparative example 1
(1) preparation of Herba Rabdosiae glaucocalycis extract：6 times of addition, 80% ethanol ultrasonic extraction of amount 2 times, extracts every time in Herba Rabdosiae glaucocalycis
40min, the alcohol extract for obtaining is filtered, filtrate concentrates, is vacuum dried to obtain Herba Rabdosiae glaucocalycis extract.
(2) preparation of Fructus Aurantii extract：Take Fructus Aurantii and crushed 10 mesh sieves, add water backflow 4 hours, connects volatile oil extractor
With reflux condensing tube, gained volatile oil beta-cyclodextrin inclusion compound makes Benexate Hydrochloride, and remaining medicinal residues add 3 times of amount decoctings
Boil, filter, after filtrate concentrate drying, gained total flavones mix with Benexate Hydrochloride, obtain final product Fructus Aurantii extract, gained Fructus Aurantii
The weight/mass percentage composition of total flavones is 14% in extract.
(3) preparation of Radix Ginseng Rubra extract：Add 5 times of 80% ethanol of amount to extract in Radix Ginseng Rubra 3 times, extract 1.5 hours every time,
The alcohol extract for obtaining is filtered, filtrate concentrates, is vacuum dried to obtain Radix Ginseng Rubra extract.
(4) by Herba Rabdosiae glaucocalycis extract, Fructus Aurantii extract and Radix Ginseng Rubra extract with mass ratio as 1：6：40 mix homogeneously, 80 mesh
Sieve, obtain pharmaceutical composition powder of the particle diameter less than 80 mesh, fill capsule.Promotion gastric motility is made in the irradiated sterilizing of capsule
Medicament composition capsule.
Comparative example 2
(1) preparation of Herba Rabdosiae glaucocalycis extract：6 times of addition, 80% ethanol ultrasonic extraction of amount 2 times, extracts every time in Herba Rabdosiae glaucocalycis
40min, the alcohol extract for obtaining adds activated carbon reflux decolour, and the dosage of activated carbon is the 3% of Herba Rabdosiae glaucocalycis crude drug quality, from
The heart, filtrate is concentrated into extractum, is dissolved with ethyl acetate, plus saturated sodium carbonate solution shaking is extracted, and ethyl acetate layer is concentrated to dryness,
It is finely ground.
(2) preparation of Fructus Aurantii extract：Take Fructus Aurantii and crushed 10 mesh sieves, add water backflow 4 hours, connects volatile oil extractor
With reflux condensing tube, gained volatile oil beta-cyclodextrin inclusion compound makes Benexate Hydrochloride, and remaining medicinal residues add 3 times of amount decoctings
Boil, filter, decocting liquid crosses NKA-9 type macroporous resins, with 4 times of ethanol elutions of column volume 50%, the concentration of eluent rotary evaporation is dry
After dry, gained total flavones with mix with Benexate Hydrochloride, obtain final product Fructus Aurantii extract, total flavones in gained Fructus Aurantii extract
Weight/mass percentage composition is 22%.
(3) preparation of Radix Ginseng Rubra extract：Add 5 times of 80% ethanol of amount to extract in Radix Ginseng Rubra 3 times, extract 1.5 hours every time,
The alcohol extract for obtaining is filtered, filtrate concentrates, is vacuum dried to obtain Radix Ginseng Rubra extract.
(4) by Herba Rabdosiae glaucocalycis extract, Fructus Aurantii extract and Radix Ginseng Rubra extract with mass ratio as 1：6：40 mix homogeneously, 80 mesh
Sieve, obtain pharmaceutical composition powder of the particle diameter less than 80 mesh, fill capsule.Promotion gastric motility is made in the irradiated sterilizing of capsule
Medicament composition capsule.
Pharmacological evaluation
Below by taking pharmaceutical composition prepared by embodiment 1 and comparative example 1～2 as an example, it is described in detail.
The impact of 1.1 pairs of rat isolated stomach flesh bars
SD rats fasting 24h before experiment, drinking-water is not limited.Its head of thumping during experiment is lethal, cuts open the belly along ventrimeson immediately
Stomach is taken, in inserting oxygen-saturated kirschner nutritional solution.Stomach is opened along greater gastric curvature, gastric content is rinsed with krebs solution, remove gastric mucosa.
At stomach bottom along ring muscle bar is obtained perpendicular to stomach long axis direction clip, along stomach long axis direction clip vertical shape flesh is obtained.In stomach bottom position
Put and cut long 8mm, width 2mm flesh bars, by the ligation of stomach smooth muscle two ends threading, one end is lain on ventilation hook, put down gently into the logical oxygen of constant temperature
In bath, the other end is lain on CFS-1J transducers, connects four-way monitor, records flesh bar contractile motion.Bath liquid filling is
20mL, 37 ± 0.5 DEG C of temperature, aeration regulation speed for it is per second appearance 1～2 bubble, stomach flesh bar start test preincubation 1h,
37 DEG C of grams of formula liquid are changed per 20min.Apply (the calibration of 1g preloaies to stomach flesh bar：Input 1g tension force), stablize 10～15s
Afterwards, load is removed, line will be traced and adjusted to 1g or so, shrink steady 2～3min, add 40 μ L pharmaceutical aqueous solutions, wherein, it is blank
Matched group adds 40 μ L deionized waters, and 2～3min is re-recorded after it is stable, removes pressure, and stomach flesh bar is with 37 DEG C of kirschner nutrition
Liquid is cleaned the state to recovery dosing.The contraction activity of stomach flesh bar is detected in experimentation with pilocarpine, is such as found
When activity is bad or loses activity, changes stomach flesh bar and proceed experiment.The steady shrinkage curve of stomach flesh bar before and after record administration
Average amplitude (90s), and observe its frequency and amplitude variations.As a result such as table 1.
Impact (n=10) of the extract of table 1 to cholinergic pathway flesh bar
Note：Drug level is with crude drug gauge；* represent and compare p ＜ 0.05 with blank control group, * * are represented and blank control group
Relatively p ＜ 0.01.
As a result show, compared with blank control group, the shrinkage amplitude of the cholinergic pathway flesh bar that motilium group and nation can organize
Without significant change.The embodiment group and comparative example group of various dose increase to varying degrees the average receipts of in vitro stomach flesh bar
Contracting degree, and there is dose-dependant；Embodiment group increases the average shrinkage amplitude of in vitro stomach flesh bar and is significantly greater than comparative example group.Together
When, embodiment low dose group can increase the contractive amplitude of stomach flesh bar.
1.2 pharmaceutical compositions affect on atropine induction gastric motility disorder mice
ICR mices 60, male and female half and half are randomly divided into blank control group (distilled water), model group (distilled water), the positive right
According to group (motilium, 0.01gKg-1), 1 group of (2gKg of embodiment-1), 1 group of (2gKg of comparative example-1), 2 groups of (2g of comparative example
Kg-1) 10 per group.After each group mice continuous gavage is administered 6 days, water 20h is can't help in fasting, tests same day gastric infusion 0.1ml/
10g, wherein blank group, model group gavage such as give at the distilled water of capacity；Gavage 30min pneumoretroperitoneum injecting atropine 2mg/kg,
Wherein blank control group such as gives at the distilled water of capacity.Each group gavage gives prepared Chinese ink 0.2ml/ only after injecting atropine 15min,
Cervical vertebra is taken off after 20min and puts to death mice, abdominal cut, ligation stomach cardia and pylorus end, taken stomach and claim stomach full weight, cut off along greater gastric curvature,
Content is washed away, weighing obtains stomach net weight, calculates gastric content residual rate, as a result as shown in table 2.
The extract of table 2 is acted on gastric motility disorder mice
Note：* represent and compare p ＜ 0.05 with model group；* is represented and is compared p ＜ 0.01 with model group；* * are represented and model group
Relatively p ＜ 0.001.
From table 2, compare with model group, in positive controls, motilium causes gastric motility disorder Mouse Stomach to atropine
Empty to have and be obviously promoted effect；In pharmaceutical composition group, the pharmaceutical composition of 1 group of preparation of embodiment causes gastric motility to atropine
The gastric emptying of obstacle mice also has significant facilitation, and effect better than pharmaceutical composition prepared by comparative example group.
Claims (10)
1. it is a kind of promote gastric motility pharmaceutical composition, it is characterised in that carried by Herba Rabdosiae glaucocalycis extract, Fructus Aurantii extract and Radix Ginseng Rubra
Thing composition is taken, wherein, the mass ratio of Herba Rabdosiae glaucocalycis extract, Fructus Aurantii extract and Radix Ginseng Rubra extract is 1～2：5～10：10～60.
2. it is according to claim 1 promote gastric motility pharmaceutical composition, it is characterised in that Herba Rabdosiae glaucocalycis extract, Fructus Aurantii
Extract is 1 with the mass ratio of Radix Ginseng Rubra extract：6：20～40.
3. the pharmaceutical composition for promoting gastric motility according to claim 1, it is characterised in that also containing edible or medicinal auxiliary
Material.
4. it is a kind of promote gastric motility pharmaceutical composition preparation method, it is characterised in that by Herba Rabdosiae glaucocalycis extract, Fructus Aurantii extract
Thing and Radix Ginseng Rubra extract are with mass ratio as 1～2：5～10：10～60 mix homogeneously, obtain described pharmaceutical composition.
5. it is according to claim 4 promote gastric motility pharmaceutical composition preparation method, it is characterised in that the scented tea
The preparation method of dish extract includes：Addition ethanol ultrasonic extraction 2～3 times in Herba Rabdosiae glaucocalycis, extract every time 20～40min, obtain
The alcohol extract for arriving plus activated carbon reflux decolour, centrifugation, filtrate is concentrated into extractum, is dissolved with ethyl acetate, plus saturated sodium carbonate is molten
Liquid shaking is extracted, and ethyl acetate layer is concentrated to dryness, finely ground.
6. it is according to claim 5 promote gastric motility pharmaceutical composition preparation method, it is characterised in that the activity
The dosage of charcoal is the 3～8% of Herba Rabdosiae glaucocalycis crude drug quality.
7. it is according to claim 5 promote gastric motility pharmaceutical composition preparation method, it is characterised in that the saturation
The dosage of sodium carbonate liquor is the 3～8% of ethyl acetate quality.
8. it is according to claim 4 promote gastric motility pharmaceutical composition preparation method, it is characterised in that the Fructus Aurantii
The preparation method of extract includes：Take Fructus Aurantii to pulverize and sieve, add water backflow 4～6 hours, connect volatile oil extractor and returned cold
Solidifying pipe, gained volatile oil beta-cyclodextrin inclusion compound makes Benexate Hydrochloride, and remaining medicinal residues are added water to cook, and filters, decocting liquid
AB-8 type macroporous resins are crossed, with 3～6 times of ethanol elutions of column volume 50%, after eluent rotary evaporation concentrate drying, gained is always yellow
Ketone mixes with Benexate Hydrochloride, obtains the Fructus Aurantii extract.
9. the preparation method of the pharmaceutical composition of the promotion gastric motility according to any one of claim 4～8, its feature exists
In also including：By obtained pharmaceutical composition, directly or edible or pharmaceutic adjuvant is added, further make capsule, piece
Agent, granule, oral liquid or powder.
10. a kind of application of the pharmaceutical composition of the promotion gastric motility according to any one of claims 1 to 3, its feature exists
In described pharmaceutical composition is preparing the application in promoting gastric motility medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611192811.1A CN106581236A (en) | 2016-12-21 | 2016-12-21 | Medicinal composition for promoting gastric motility, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611192811.1A CN106581236A (en) | 2016-12-21 | 2016-12-21 | Medicinal composition for promoting gastric motility, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106581236A true CN106581236A (en) | 2017-04-26 |
Family
ID=58602389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611192811.1A Pending CN106581236A (en) | 2016-12-21 | 2016-12-21 | Medicinal composition for promoting gastric motility, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106581236A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107362220A (en) * | 2017-08-02 | 2017-11-21 | 杭州胡庆余堂药业有限公司 | A kind of application of pharmaceutical composition in the Chinese medicine preparation for preparing treatment functional dyspepsia FD |
| CN110123927A (en) * | 2019-06-21 | 2019-08-16 | 南京致中生物科技有限公司 | A kind of colloidal bismmth pectin complex capsule and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709421A (en) * | 2005-06-17 | 2005-12-21 | 吕宝俊 | Medicinal formulation for preventing and treating stomach and digestive tract diseases |
| CN1927298A (en) * | 2006-07-28 | 2007-03-14 | 杭州胡庆余堂药业有限公司 | Traditional Chinese medicine preparation for treating stomach and intestinal disease and its preparation |
-
2016
- 2016-12-21 CN CN201611192811.1A patent/CN106581236A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709421A (en) * | 2005-06-17 | 2005-12-21 | 吕宝俊 | Medicinal formulation for preventing and treating stomach and digestive tract diseases |
| CN1927298A (en) * | 2006-07-28 | 2007-03-14 | 杭州胡庆余堂药业有限公司 | Traditional Chinese medicine preparation for treating stomach and intestinal disease and its preparation |
Non-Patent Citations (3)
| Title |
|---|
| 付立娟等: "枳壳挥发油包合工艺的优化", 《安徽农业科学》 * |
| 许崇瑶等: "枳壳提取物的制备工艺研究", 《中国中药杂志》 * |
| 陈笔岫: "鄂西香茶菜的二萜―4-表鄂西香茶素A", 《国外医药 植物药分册》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107362220A (en) * | 2017-08-02 | 2017-11-21 | 杭州胡庆余堂药业有限公司 | A kind of application of pharmaceutical composition in the Chinese medicine preparation for preparing treatment functional dyspepsia FD |
| CN110123927A (en) * | 2019-06-21 | 2019-08-16 | 南京致中生物科技有限公司 | A kind of colloidal bismmth pectin complex capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103990081B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice | |
| CN104208302A (en) | Fructus rosae laevigatae healthy oral solution for reducing blood fat and preparation method thereof | |
| CN104083727A (en) | Traditional Chinese medicine composition for nourishing and protecting liver | |
| CN104547853A (en) | Traditional Chinese medicine composition for adjusting intestinal flora, strengthening stomach and helping digestion | |
| CN101461932B (en) | Medicament composition for treating children's damp-heat diarrhea induced by spleen insufficiency and preparation method thereof | |
| CN106581236A (en) | Medicinal composition for promoting gastric motility, and preparation method and application thereof | |
| CN101007157A (en) | Traditional Chinese medicine compound preparation for treating chronic cholecystitis | |
| CN102406714B (en) | Pharmaceutical composition favorable for defaecation and preparation method thereof | |
| CN101890062B (en) | Use of nardostachys chinensis batal and extract thereof in preparation of medicaments for treating gastric ulcer | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN105250954B (en) | A kind of Chinese medicine for treating IBS and preparation method thereof | |
| CN104547523A (en) | Medicine for enhancing immunity and preparation method thereof | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN105412424A (en) | Pharmaceutical preparation containing argy wormwood leaves and having bowel relaxing function as well as preparation method of pharmaceutical preparation | |
| CN101549140B (en) | Traditional Chinese medicine composition for treating AIDS and preparation method thereof | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN108404068B (en) | Pharmaceutical composition for treating and/or preventing diarrhea and preparation method thereof | |
| CN105726590A (en) | Chinese herbal medicine preparation with functions of reducing alcohol absorption and protecting liver | |
| CN101214302A (en) | Pharmaceutical compositions for treating melancholia associated with functional dyspepsia and preparation | |
| CN104147245B (en) | A kind of salsola collina composition, its preparation method and its application in Weight-lossing hypolipemic medicine is prepared | |
| CN105125693A (en) | Traditional Chinese medicine composition for treating acute gastritis and preparing method thereof | |
| CN105031364A (en) | Preparation for preventing and treating toothache due to wind-fire evil and preparation method of preparation | |
| CN105535895B (en) | Traditional Chinese medicine composition for treating productive coughs | |
| CN115177664A (en) | Traditional Chinese medicine composition, traditional Chinese medicine preparation and traditional Chinese medicine product for treating cardiovascular and cerebrovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |
|
| RJ01 | Rejection of invention patent application after publication |